drugset
drugset / Trial / NCT03092999

Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)

NCT03092999 ↗

Phase 1 Completed 36 enrolled Bayer
Non-randomizedParallel-groupOpen-labelOther

Summary

Evaluate the potential effect of hepatic impairment on the pharmacokinetics, safety and tolerability of BAY1002670 (vilaprisan)

Timeline

Start
2017-03-28
Primary completion
2017-07-17
Completion
2017-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Vilaprisan Other / unclassified 2 mg Oral

Indications

leiomyoma